J Korean Med Assoc.  2011 Apr;54(4):401-408. 10.5124/jkma.2011.54.4.401.

Craving and treatment in smoking

• Kim MH
• Min S

• KMID: 2190424
• DOI: http://doi.org/10.5124/jkma.2011.54.4.401

Abstract

Craving has been well known to be the most important clinical phenomenon in smoking cessation treatment and one that physicians always encounter. For successful and prolonged abstinence, understanding, evaluation, and management of craving are essential. The concept and definition of craving is still under debate, although its importance, relevance, and role in smoking relapse is evident. There are two types of craving, 'abstinence-induced craving' and 'cue-induced craving' according to time dynamic and causes. The evaluation of craving mainly depends on self-reported measures in the clinical field. Pharmacological treatments such as the nicotine patch, bupropion, and varenicline are effective for abstinence-induced craving. Psychosocial treatment and a few pharmacological agents such as nicotine gum and lozenges are useful for reducing cue-induced craving. This review was aimed at conveying up-to-date information on the characteristics, evaluation, and treatment of craving. Development of objective measurement tool for evaluation of craving is needed. The effects of pharmacological treatments on 'cue-induced craving' remain to be discovered. An active effort to alleviate each type of craving is necessary to enhance and prolong a patient's abstinence.

Keyword

Smoking; Tobacco use disorder; Craving; Urge

MeSH Terms

Benzazepines
Bupropion
Gingiva
Nicotine
Quinoxalines
Recurrence
Smoke
Smoking
Smoking Cessation
Tobacco Use Cessation Products
Tobacco Use Disorder
Varenicline
Benzazepines
Bupropion
Nicotine
Quinoxalines
Smoke

Reference

1. Perkins KA, Conklin CA, Levine MD. Cognitive-behavioral therapy for smoking cessation: a practical guidebook to the most effective treatments. 2008. New York: Routledge;258.

2. Shiffman S, West R, Gilbert D. SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res. 2004. 6:599–614.

3. Donovan DM, Marlatt GA. Assessment of addictive behaviors. 2005. 2nd ed. New York: Guilford Press;480.

4. Sayette MA, Shiffman S, Tiffany ST, Niaura RS, Martin CS, Shadel WG. The measurement of drug craving. Addiction. 2000. 95:Suppl 2. S189–S210.

5. Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C. Hormonal, psychological, and alcohol craving changes after m- Chlorophenylpiperazine administration in alcoholics. Alcohol Clin Exp Res. 1997. 21:220–227.

6. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991. 86:1467–1476.

7. Kozlowski LT, Wilkinson DA. Use and misuse of the concept of craving by alcohol, tobacco, and drug researchers. Br J Addict. 1987. 82:31–36.

8. Kassel JD, Shiffman S. What can hunger teach us about drug craving? A comparative analysis of the two constructs. Adv Behav Res Ther. 1992. 14:141–167.

9. Shiffman S. Comments on craving. Addiction. 2000. 95:Suppl 2. S171–S175.

10. Perkins KA. Does smoking cue-induced craving tell us anything important about nicotine dependence? Addiction. 2009. 104:1610–1616.

11. Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat. 2009. 36:235–243.

12. Miyata H, Yanagita T. Neurobiological mechanisms of nicotine craving. Alcohol. 2001. 24:87–93.

13. Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol. 1997. 5:137–142.

14. Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M. A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol. 1997. 106:104–116.

15. Kozlowski LT, Pillitteri JL, Sweeney CT, Whitfield KE, Graham JW. Asking questions about urges or cravings for cigarettes. Psychol Addict Behav. 1996. 10:248–260.

16. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001. 3:7–16.

17. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl). 2003. 166:343–350.

18. Heishman SJ, Singleton EG, Moolchan ET. Tobacco Craving Questionnaire: reliability and validity of a new multifactorial instrument. Nicotine Tob Res. 2003. 5:645–654.

19. Choi KS, Lee CH, Yu JC, Kim SJ, Choi HJ, Jeong BS. The reliability and validity of the Korean version of tobacco craving questionnaire. J Korean Neuropsychiatr Assoc. 2008. 47:161–167.

20. Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, Di Marino ME. Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction. 2000. 95:1185–1195.

21. Kim SS, Gulick EE, Kim SH, Seo HG. Psychometric properties of the Minnesota Nicotine Withdrawal Scale: a Korean version. J Nurs Meas. 2007. 15:121–132.

22. Niaura R, Shadel WG, Abrams DB, Monti PM, Rohsenow DJ, Sirota A. Individual differences in cue reactivity among smokers trying to quit: effects of gender and cue type. Addict Behav. 1998. 23:209–224.

23. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl). 2006. 184:637–644.

24. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology (Berl). 2002. 164:177–187.

25. Shiffman S, Khayrallah M, Nowak R. Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation. Nicotine Tob Res. 2000. 2:371–378.

26. Kim DJ, Joe KH. Korean Academy of Addiction Psychiatry. Nicotine dependence. Addiction psychiatry. 2009. Seoul: ML Communication;225–242.

27. Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol. 2000. 68:233–240.

28. Schneider NG, Cortner C, Gould JL, Koury MA, Olmstead RE. Comparison of craving and withdrawal among four combi-nation nicotine treatments. Hum Psychopharmacol. 2008. 23:513–517.

29. Rezaishiraz H, Hyland A, Mahoney MC, O'Connor RJ, Cummings KM. Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings? Nicotine Tob Res. 2007. 9:1139–1146.

30. Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, Rigotti N, Sachs DP. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther. 2002. 24:540–551.

31. Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006. 6:965–981.

32. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A. Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology (Berl). 2005. 183:1–12.

33. Culbertson CS, Bramen J, Cohen MS, London ED, Olmstead RE, Gan JJ, Costello MR, Shulenberger S, Mandelkern MA, Brody AL. Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch Gen Psychiatry. 2011. 01. 03. [Epub]. DOI: 10.1001/archgenpsychiatry.2010.193.

34. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008. 63:717–724.

35. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006. 296:47–55.

36. Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med. 2008. 121:4 Suppl 1. S32–S42.

37. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008. 197:371–377.

38. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, Detre JA, O'Brien CP, Childress AR. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry. 2011. 01. 03. [Epub]. DOI: 10.1001/archgenpsychiatry.2010.190.

39. Piasecki M. Nicotine in psychiatry: psychopathology and emerging therapeutics. 2000. Washington, DC: American Psychiatric Press;279.

40. Abrams DB, Niaura R, Brown RA, Emmons KM, Goldstein MG, Monti PM. The tobacco dependence treatment handbook: a guide to best practices. 2003. New York: Guilford Press;365.

41. Lee JH, Ku J, Kim K, Kim B, Kim IY, Yang BH, Kim SH, Wiederhold BK, Wiederhold MD, Park DW, Lim Y, Kim SI. Experimental application of virtual reality for nicotine craving through cue exposure. Cyberpsychol Behav. 2003. 6:275–280.

42. Moon J, Lee JH. Cue exposure treatment in a virtual environ-ment to reduce nicotine craving: a functional MRI study. Cyberpsychol Behav. 2009. 12:43–45.